Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to recurrent skin cancers. The biotech company said the discussions focused on securing orphan drug designation for SkinJect for Gorlin syndrome, registrational investigational new drug approval for affected patients, and support for the rare disease pediatric FDA voucher program.